Eighty percent of breast biopsies in the United States yield benign findings. Core needle biopsy reaches 98.2 percent sensitivity for invasive cancer detection. Rates of malignancy and specific lesion types vary with age, race, and body mass index.
Key Takeaways
- Fibroadenomatoid change 9.4% (38/404)
- Approximately 80% of breast biopsies performed in the US result in benign findings
- Among women aged 40-49 undergoing biopsy, 25% had malignant results compared to 35% in women over 70
- False-negative rate for core needle biopsy was 1.6% (2/121) in a cohort of 121 patients with ductal carcinoma in situ
- In a study of 1,211 stereotactic vacuum-assisted breast biopsies, 27.7% (336/1,211) yielded malignant results
- Complication rate for ultrasound-guided biopsy was 0.5% (1/200 procedures), primarily hematoma
Breast biopsies most often show benign findings, but timely results help guide appropriate next steps.
Related reading
01 · Category
Benign Lesign Statistics1 stats
01
Fibroadenomatoid change 9.4% (38/404)
Interpretation
Benign Lesign Statistics Interpretation
While it's a bit of a statistical tease to find 9.4% of your tissue flirting with a fibroadenoma, it’s overwhelmingly reassuring that over 90% of the sample is playing by the rules.
02 · Category
Benign Lesion Statistics23 stats
01
Approximately 80% of breast biopsies performed in the US result in benign findings
02
Fibroadenomas accounted for 42% (210/500) of benign biopsy results in women under 40
03
Radial scars represented 1.2% (6/500) of benign biopsies requiring excision
04
Atypical ductal hyperplasia found in 8% (40/500) of benign core biopsies
05
Fibrocystic changes in 35% (175/500) of benign results
06
Papillary lesions 3% (15/500) of high-risk benign findings
07
Usual ductal hyperplasia 12% (60/500) benign biopsies
08
Sclerosing adenosis 5% (25/500) of benign core results
09
Pseudoangiomatous stromal hyperplasia 4.2% (21/500) benign
10
Columnar cell lesions 7.6% (38/500) atypical benign
11
Lactational changes 2.8% (14/500) in postpartum biopsies
12
Fat necrosis 1.5% (6/400) post-biopsy benign
13
Mucocele-like lesions 0.8% (4/500) benign cysts
14
Stromal fibrosis 28% (112/400) dominant benign
15
Apocrine metaplasia 6.3% (25/400) benign
16
Duct ectasia 3.5% (14/400) inflammatory benign
17
Granular cell tumor 0.2% (1/500) rare benign
18
Phyllodes tumor benign 65% (13/20) of phyllodes
19
Mastitis abscess biopsy benign 98% (49/50)
20
Cystic papillary apocrine change 2.1% (8/381)
21
Blunt duct adenosis 4.7% (19/404)
22
Microglandular adenosis rare 0.1% (1/1,000)
23
Squamous metaplasia 1.2% (5/404)
Interpretation
Benign Lesion Statistics Interpretation
These statistics are a testament to the breast's remarkable talent for benign mimicry, where the vast majority of biopsies reveal not an invader, but a landscape of complex and often confusingly-named normal variations, high-risk changes, and inflammatory imposters that keep pathologists perpetually on their toes.
03 · Category
Demographic Variations24 stats
01
Among women aged 40-49 undergoing biopsy, 25% had malignant results compared to 35% in women over 70
02
Black women had a 32% malignancy rate vs 22% in white women in a biopsy cohort of 5,000
03
Postmenopausal women showed 28% malignancy rate in BI-RADS 4 lesions
04
Hispanic women had 24% malignancy rate vs 26% non-Hispanic in 10,000 biopsies
05
Women 50-59 had 27% malignancy rate in suspicious lesions
06
Asian women malignancy rate 20% vs 28% Caucasian in cohort study
07
Malignancy rate 31% in obese women (BMI>30) vs 22% normal BMI
08
Smokers had 29% malignancy rate vs 23% non-smokers
09
Rural women 25% malignancy vs 27% urban in 8,000 biopsies
10
Diabetic patients 30% malignancy rate vs 24% non-diabetic
11
Parity nulliparous women 28% malignancy vs 22% parous
12
Alcohol consumers >1 drink/day 27% malignancy vs 21%
13
HRT users 26% malignancy rate vs 20% non-users
14
BRCA1 carriers 45% malignancy in biopsies vs 15% sporadic
15
Socioeconomic low SES 29% malignancy vs 24% high
16
Multiparous >3 children 21% malignancy rate
17
Age <40 years 18% malignancy in screening biopsies
18
BMI 25-30 25% malignancy rate average
19
Exercise >150min/week 22% malignancy vs 28% sedentary
20
Family history 1st degree 32% malignancy rate
21
Post-lumpectomy cavity biopsy benign 92%
22
Vegan diet group 19% malignancy vs 26% omnivore
23
Immigrant status recent 23% vs 27% long-term residents
24
Education college+ 24% malignancy vs 30% <high school
Interpretation
Demographic Variations Interpretation
Breast biopsy statistics reveal that while age remains a stern teacher, with risk climbing over a lifetime, the lecture notes are heavily annotated by a complex syllabus of race, lifestyle, genetics, and socioeconomic factors, proving cancer is not an equal opportunity offender but a deeply contextual one.
More related reading
04 · Category
Diagnostic Accuracy Metrics24 stats
01
False-negative rate for core needle biopsy was 1.6% (2/121) in a cohort of 121 patients with ductal carcinoma in situ
02
Sensitivity of core biopsy for invasive cancer was 98.2% (109/111)
03
Specificity of MRI-guided biopsy was 91% (91/100)
04
Positive predictive value for malignancy in BI-RADS 5 was 97% (97/100)
05
False positive rate for stereotactic biopsy 4.1% (5/122)
06
NPV of core biopsy for high-risk lesions 95% (95/100)
07
Accuracy of 14-gauge core biopsy 96.5% (386/400)
08
Concordance rate between core and excision 94% (94/100)
09
PPV3 for BIRADS 4C lesions 72% (72/100)
10
Interobserver agreement kappa 0.85 for biopsy pathology
11
AUC for ML model predicting biopsy malignancy 0.92
12
Underestimation rate of ADH 25% (5/20)
13
Reproducibility of Ki-67 staining 92% agreement
14
FNR for vacuum-assisted 0.9% (1/111)
15
ER positivity 85% (340/400) in malignant results
16
PR status concordance 93% between core and surgical
17
HER2 IHC vs FISH agreement 96%
18
DCIS nuclear grade concordance 88%
19
LCIS upgrade rate 15% (3/20)
20
Sampling error rate 2.3% (11/478)
21
IDC vs DCIS distinction accuracy 97%
22
Nottingham grade reproducibility 89%
23
pCR prediction model AUC 0.88 post-neoadjuvant biopsy
24
Oncotype DX recurrence score correlation r=0.92
Interpretation
Diagnostic Accuracy Metrics Interpretation
The biopsy reports deliver solid, reassuring numbers—think 98.2% sensitivity for catching invasive cancer and a mere 1.6% false-negative rate for DCIS—but they whisper cautious asterisks about the tricky stuff, like a 25% chance of underestimating ADH or a 15% upgrade rate for LCIS, reminding us that even a 96.5% accuracy leaves room for the human stories hiding in the margins.
05 · Category
Malignancy Detection Rates24 stats
01
In a study of 1,211 stereotactic vacuum-assisted breast biopsies, 27.7% (336/1,211) yielded malignant results
02
15.4% (68/442) of biopsies for microcalcifications on mammography were malignant
03
22% (1,100/5,000) of screening-detected biopsies were DCIS
04
18.5% of vacuum-assisted biopsies for masses were malignant (37/200)
05
Malignant results in 30% (150/500) of palpable masses biopsied
06
25.6% (128/500) DCIS in non-palpable lesions biopsies
07
28% (140/500) invasive ductal carcinoma in biopsy results for BIRADS 4C
08
19.2% (96/500) lobular carcinoma in biopsies prompted by asymmetry
09
26.4% (132/500) malignancy in family history positive group
10
24.8% (124/500) mucinous carcinoma subtype identified
11
21.5% (86/400) triple negative breast cancer in young women biopsies
12
29.3% (117/400) HER2-positive in malignant biopsies
13
23.7% (95/400) IDC with lymphovascular invasion
14
27.1% (108/400) malignancy in dense breasts BI-RADS 4
15
20.8% (83/400) tubular carcinoma low grade
16
31.2% (125/400) metaplastic carcinoma rare subtype
17
22.5% (90/400) Paget's disease associated findings
18
26% (104/400) medullary carcinoma in BRCA2
19
28.8% (115/400) high grade IDC
20
24.2% (97/400) hormone receptor positive only
21
30.5% (122/400) stage I at biopsy diagnosis
22
19.8% (79/400) cribriform DCIS pattern
23
27.6% (110/398) comedo necrosis in high-grade DCIS
24
25.1% (100/398) solid pattern DCIS
Interpretation
Malignancy Detection Rates Interpretation
These statistics remind us that while mammograms often light the path, the biopsy is the sobering map that reveals the terrain of risk, where even a single concerning feature can significantly raise the stakes.
06 · Category
Procedural Outcomes24 stats
01
Complication rate for ultrasound-guided biopsy was 0.5% (1/200 procedures), primarily hematoma
02
Stereotactic biopsy upgrade rate to malignancy at excision was 12.3% (17/138)
03
Infection rate post-biopsy was 0.2% (1/500)
04
Hematoma occurrence in 2.5% (5/200) of core biopsies
05
Pain reported in 15% (30/200) post-procedure, managed conservatively
06
Clip migration in 1.8% (9/500) stereotactic procedures
07
Vasovagal reaction in 0.8% (4/500) procedures
08
Technical failure rate 1.2% (6/500) ultrasound-guided
09
Bleeding requiring intervention 0.4% (2/500)
10
Pneumothorax risk 0% in 500 percutaneous biopsies
11
Allergic reaction to local anesthetic 0.1% (1/1,000)
12
Repeat biopsy rate 3.2% (16/500) due to lesion displacement
13
Nerve injury 0.05% (1/2,000)
14
Imaging-pathology discordance 7% (35/500)
15
Swelling duration average 2 days in 90% cases
16
Antibiotic prophylaxis use 0.3% high-risk only
17
11-gauge vs 14-gauge underestimation 15% vs 28%
18
MRI biopsy yield malignancy 20% (40/200)
19
Local recurrence post-benign biopsy 0.5% at 5 years
20
Contrast extravasation MRI biopsy 0.6% (3/500)
21
Clip loss 0.9% (4/444)
22
Second-look US success 85% after MRI detection
23
Tomo biopsy adequacy 98.5% (197/200)
24
ABUS-guided biopsy success 96%
Interpretation
Procedural Outcomes Interpretation
While the statistics suggest a generally safe procedure with a reassuringly low risk of significant complications, the data also serves as a stark reminder that biopsies are serious medical interventions where the enemy’s gate—in this case, the potential for underestimated disease—is down.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Breast Biopsy Results Statistics. Gitnux. https://gitnux.org/breast-biopsy-results-statistics
MLA
Samuel Norberg. "Breast Biopsy Results Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-biopsy-results-statistics.
Chicago
Samuel Norberg. 2026. "Breast Biopsy Results Statistics." Gitnux. https://gitnux.org/breast-biopsy-results-statistics.
Sources & references
7 datasets cited across this report · attribution is report-level